Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and new antimicrobial agents.

George M Eliopoulos1

  • 1Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. geliopou@caregroup.harvard.edu

American Heart Journal
|April 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Updated History of <i>Antimicrobial Agents and Chemotherapy</i>: 2000-2020.

Antimicrobial agents and chemotherapy·2020
Same author

Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres.

Journal of global antimicrobial resistance·2020
Same author

Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.

Antimicrobial agents and chemotherapy·2018
Same author

Invitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

Diagnostic microbiology and infectious disease·2017
Same author

Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral Antibiotics.

Antimicrobial agents and chemotherapy·2016
Same author

Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.

International journal of antimicrobial agents·2015
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
Same journal

Considerations for Using Atrial Fibrillation Burden as a Surrogate Endpoint A Report from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

Prognostic Impact of Combined Inflammatory Markers in Patients Undergoing Percutaneous Coronary Intervention.

American heart journal·2026
See all related articles

Newer antibiotics show promising in vitro activity against staphylococci, offering potential alternatives for cardiovascular surgery patients with resistant infections. These agents may overcome resistance to older drugs.

Area of Science:

  • Infectious Diseases
  • Cardiovascular Surgery
  • Microbiology

Background:

  • Bacterial infections, particularly Staphylococci, pose significant risks in cardiovascular surgery.
  • Staphylococcal infections often exhibit resistance to conventional antibiotic therapies.

Purpose of the Study:

  • To review newer antimicrobial agents for their in vitro efficacy against staphylococci.
  • To identify potential treatment options for Staphylococci infections in cardiovascular surgery.

Main Methods:

  • Literature review of approved and investigational antimicrobial agents.
  • Focus on in vitro activity data against staphylococci.

Main Results:

  • Several agents, including linezolid, quinupristin-dalfopristin, daptomycin, oritavancin, and dalbavancin, demonstrate in vitro anti-staphylococcal activity.

Related Experiment Videos

  • Daptomycin is FDA-approved; oritavancin and dalbavancin are in late-stage development.

    • Conclusions:

    • Emerging antimicrobial agents show potential for treating staphylococcal infections.
    • These newer drugs may serve as valuable alternatives for patients with antibiotic-resistant infections or intolerance to older treatments.